EUVIMEDOpdag EUVIMED
Multizentrische StudieKlinische Studie (Phase IV)

Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study

Sundeep Upadhyaya, Uma Kumar, Srikantiah Chandrashekara, Venkataraman Krishnamurthy, Syamasis Bandyopadhyay, Ajit Surin, Liza Rajasekhar, Neeraj Jain, Ajit Nalawade, Sagar Panchal, Nishita Shah, Tanuja Korde and 1 more

Journal of the Association of Physicians of India · 2024-03 · 72 (3) · 40-46

DOI: 10.59556/japi.72.0485 ↗

At a glance

Multizentrische Studie in Journal of the Association of Physicians of India, 2024-03. Written by Sundeep Upadhyaya and 12 co-authors. Institution: Senior Consultant Rheumatologist, Department of Rheumatology, Indraprastha Apollo Hospitals, New Delhi, Delhi, India. Major MEDLINE topics: Antibodies, Monoclonal, Arthritis, Psoriatic, Spondylitis, Ankylosing. Cited 4 times so far (Crossref); 36 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: The safety and efficacy of tumor necrosis factor-α (TNF-α) inhibitor therapy for most common rheumatological diseases, ankylosing spondylitis (AS), and psoriatic arthritis (PsA) in controlled clinical trials is well-studied. This study evaluated subcutaneous (SC) golimumab in Indian patients with active spondyloarthritis (SpA) of AS or PsA in a real-world setting. MATERIALS AND METHODS: This phase 4, multicenter, prospective, non-comparative, interventional, 24-week study was performed in patients (age ≥18 years) with active SpA of AS or PsA (NCT03733925). Golimumab 50 mg was given subcutaneously to the patients every 4 weeks. Safety was assessed. The proportion of patients with AS and PsA achieving ≥20% improvement in the Assessment of SpA International Society 20 (ASAS20) criteria and American College of Rheumatology 20 (ACR20) responses, respectively, at weeks 14 and 24 were efficacy endpoints. RESULTS: Of the 100 patients enrolled (men: 78 [78.0%]; mean age: 36.7 [12.02] years), 94 (94.0%) patients completed the study. Treatment-emergent adverse events with golimumab were observed in 29/100 (29.0%) patients, and nasopharyngitis and upper respiratory tract infection (5.0% each) were the most common (≥5%). Deaths were not reported. At week 14, 74.5% (95% confidence interval [CI]: 59.7; 86.1%) of patients with AS and 84.6% (95% CI: 69.5; 94.1%) of patients with PsA achieved ASAS20 and ACR20 responses, which were sustained at week 24 (ASAS20: 66.0% [95% CI: 50.7, 79.1%]; ACR20: 93.2% [95% CI: 81.3, 98.6%]), respectively. CONCLUSION: Golimumab (50 mg) administered subcutaneously was safe and effective in Indian patients with active SpA of AS or PsA during the 24-week study period with no new safety signals.

Subjects

MeSH terms (MEDLINE)

Antibodies, MonoclonalArthritis, PsoriaticSpondylitis, AnkylosingHumansAdultMaleFemaleIndiaProspective StudiesMiddle AgedTreatment OutcomeInjections, SubcutaneousAntirheumatic Agents

Substances

golimumabAntibodies, MonoclonalAntirheumatic Agents

Authors and institutions

  • Senior Consultant Rheumatologist, Department of Rheumatology, Indraprastha Apollo Hospitals, New Delhi, Delhi, India.
  • Head, Department of Rheumatology, All India Institute of Medical Sciences (AIIMS), New Delhi, Delhi, India.
  • Medical Director & Consultant Rheumatologist, Department of Clinical Immunology & Rheumatology, ChanRe Rheumatology & Immunology Center & Research, Bengaluru, Karnataka, India.
  • Consultant Rheumatologist, Department of Rheumatology, Chennai Meenakshi Multispecialty Hospital, Chennai, Tamil Nadu, India.
  • Senior Consultant Physician, Department of Internal Medicines and Rheumatology, Apollo Gleneagles Hospital, Kolkata, West Bengal, India.
  • Senior Consultant Rheumatologist, Department of Rheumatology, Apollo Hospital, Bhubaneswar, Odisha, India.

Cite

APA

Upadhyaya, S., Kumar, U., Chandrashekara, S., Krishnamurthy, V., Bandyopadhyay, S., Surin, A., Rajasekhar, L., Jain, N., Nalawade, A., Panchal, S., Shah, N., Korde, T., & Dixit, J. (2024). Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study. Journal of the Association of Physicians of India, 72(3), 40-46. https://doi.org/10.59556/japi.72.0485

Vancouver

Upadhyaya S, Kumar U, Chandrashekara S, Krishnamurthy V, Bandyopadhyay S, Surin A, et al. Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study. Journal of the Association of Physicians of India. 2024;72(3):40-46. doi:10.59556/japi.72.0485

BibTeX
@article{Upadhyaya2024,
  author = {Upadhyaya, Sundeep and Kumar, Uma and Chandrashekara, Srikantiah and Krishnamurthy, Venkataraman and Bandyopadhyay, Syamasis and Surin, Ajit and Rajasekhar, Liza and Jain, Neeraj and Nalawade, Ajit and Panchal, Sagar and Shah, Nishita and Korde, Tanuja and Dixit, Jitendra},
  title = {Safety and Efficacy of Golimumab in Indian Patients with Active Spondyloarthritis of Ankylosing Spondylitis or Psoriatic Arthritis: A Multicenter, Noncomparative, Open-Label, Real-World Study},
  journal = {Journal of the Association of Physicians of India},
  year = {2024},
  volume = {72},
  number = {3},
  pages = {40--46},
  doi = {10.59556/japi.72.0485}
}
Start for free →